Kisqali Plus Femara Seems Best Option for Advanced-Stage Hormone-Receptor-Positive HER2-Negative Breast Cancer

Dr. Gabriel Hortobagyi is professor of breast medical oncology at the University of Texas MD Anderson Cancer Center. He is a past president of the American Society of Clinical Oncology and is one of the world’s leading authorities on breast cancer treatment. He has published more than 1,000 papers in peer-reviewed journals.

At the European Society for Medical Oncology Congress 2021, Dr. Hortobagyi presented overall survival results from the MONALEESA-2 trial, which compared the combination of Kisqali and Femara to Femara alone to treat advanced-stage hormone-receptor-positive HER2-negative breast cancer in postmenopausal women. Earlier results from the study found that adding Kisqali to Femara improved progression-free survival — the amount of time the women lived without the cancer growing. These new results found that the combination of Kisqali and Femara also improved overall survival — the length of time women lived whether the cancer grew or not.

Listen to the episode to hear Dr. Hortobagyi explain:

• the goals of the MONALEESA-2 study
• why the overall survival difference of more than 1 year is so important
• whether the improvement in overall survival is likely to be the same no matter which aromatase inhibitor is used
• what the results mean for postmenopausal women diagnosed with advanced-stage hormone-receptor-positive HER2-negative breast cancer